{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 40 of 92', 'CR845-CLIN3102', 'Table 1.', 'Restricted and Prohibited Medications', 'Drug, Drug Class, or Treatment', 'Restrictions During the Treatment Period', 'Investigational drug (other than the study', 'Not allowed', 'drug)', 'Ultraviolet light-B treatments', 'Not allowed', 'Naloxone, naltrexone, or mixed', 'Not allowed from the start of dosing of the', 'agonist-antagonists (eg, buprenorphine and', 'Double-blind Treatment Period to the end of', 'nalbuphine)', 'the Open-label Treatment Period, unless', 'needed to treat an adverse event or emergent', 'medical condition acutely.', 'Antihistamines (oral, IV, or topical)', 'Changes to current prescription should be', 'avoided from screening to the end of the', 'Corticosteroids (oral, IV, or topical)', 'Double-blind Treatment Period unless for the', 'treatments', 'acute treatment of an adverse event or', 'Opioids', 'emergent medical condition (in this case,', 'notify the study medical monitor and, as', 'Gabapentin, pregabalin', 'appropriate, report adverse events).', 'No new medication to treat itch should be', 'initiated.', 'All new concomitant medications or change of frequency and doses of a concomitant', 'medication will be recorded.', '6.5', 'Study Assessments and Procedures', '6.5.1', 'Schedule of Events for the Double-blind Phase', 'Study procedures for the Double-blind Treatment Period are summarized in Table 2.', 'An ICF will need to be signed prior to initiation of the Screening Visit and any procedures', 'that follow.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 42 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 41 of 92', 'CR845-CLIN3102', 'Table 2.', 'Schedule of Events: Double-blind Phase', 'Study Procedures', 'Double-blind End of', 'Screening', 'Run-in', 'Treatmentb/', 'Discontinuation', 'Visit9', 'Period\u00ae', 'Double-blind Treatment Perioda', 'Early Termination', 'Period', 'Day -28 to', 'Day -7 to', 'Day -7', 'Day 1', 'Week 1', 'Week 2 to 12', 'Week 13', 'DP Days 2b-14', 'Visit Days', 'M/Tu', 'W/Th', 'F/Sa', 'M/Tu', 'W/Th', 'F/Sa', '-28 to -7', '-7 to 1', '1', '3', '5', '8', '10', '12', '85', '85 to 98', '15', '17', '19', '22', '24', '26', '29m', '31', '33', '36', '38', '40', '43', '45', '47', '50', '52', '54', '57 m', '59', '61', '64', '66', '68', '71th', '73', '75', '78', '80', '82', 'Administrative procedures', 'Informed consent', 'X', 'Inclusion/exclusion criteria', 'X', 'Medical history/Prior Medications (including', 'X', 'Xc', 'antipruritic medications)/Demographics', 'Randomization', 'Safety and efficacy evaluations', 'Physical examination', 'X', 'Prescription dry body weight', 'X', 'Pre-dialysis 12-lead electrocardiogramd', 'xd', 'xd', 'Pre-dialysis vital signs', 'X', 'Xe', 'Xe', 'Xe', 'xt', 'Hematology, serum chemistry (pre-dialysis)8', 'X', 'x', 'X', 'Serum pregnancy (females of childbearing', 'X', 'X', 'potential only)', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 43 of 95']\n\n###\n\n", "completion": "END"}